Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Parallel-group, Phase III Study of MRA-SC in Rheumatoid Arthritis Patients with Inadequate Response to Tocilizumab Subcutaneous Injection 162 mg every 2 weeks

Next Previous
Trial Profile

A Randomized, Double-blind, Parallel-group, Phase III Study of MRA-SC in Rheumatoid Arthritis Patients with Inadequate Response to Tocilizumab Subcutaneous Injection 162 mg every 2 weeks

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms SHINOBI
  • Sponsors Chugai Pharmaceutical

    • Most Recent Events

    • 26 Jun 2017 According to a Chugai Pharmaceutical media release, the company obtained an approval by the Ministry of Health, Labour and Welfare (MHLW) for the additional dosage and administration of Actemra Subcutaneous Injection, reducing the dose interval to one week in patients with rheumatoid arthritis who inadequately respond to the bi-weekly dosage.
    • 16 May 2017 Status changed from active, no longer recruiting to completed.
    • 25 Aug 2016 According to a Chugai Pharmaceutical media release, the company filed an application with the Ministry of Health, Labour and Welfare (MHLW) for the approval of an additional dosage of Actemra (Tocilizumab) Subcutaneous injection in patients with rheumatoid arthritis who inadequately respond to the every other week dosing regimen.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top